ArticleFrontiers in pharmacology2020
Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study.
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Reimbursement decision-making system in Poland systematically compared to other countries.Frontiers in pharmacology · 2023Pooled it
- A systematic review of the early dialogue frameworks used within health technology assessment and their actual adoption from HTA agencies.Frontiers in public health · 2022Pooled it
- Value in app store metadata and user reviews: A dual perspective on quality of Parkinson's and dementia apps.PLOS digital health · 2026Article
- The Post-Authorisation Maze: Mapping of European Pharmaceutical Market Access Pathways in the Early JCA Era.Journal of market access & health policy · 2026Article
- Trends in EU regulatory assessment of oncology medicines.ESMO open · 2026Article
- HTA submission strategies and their associations with rollout times and type of HTA recommendation in Australia and Canada.International journal of technology assessment in health care · 2026Observational
- Exploring the Generalizability of Foreign Cost-Effectiveness Analysis to Spain Using Data From a Scoping Review of Multinational Studies.PharmacoEconomics · 2026Article
- Mathematical modelling and time series clustering of Mpox outbreak: A comparative study of the top 10 affected countries and implications for future outbreak management.Global epidemiology · 2025Article
- Importance of Health Economics and Outcomes Research in the Product Lifecycle.Pharmaceutical medicine · 2025Review
- Using patient-reported outcome measures in clinical trials: perspectives for and against a modular approach.The Medical journal of Australia · 2025Article
- Methods for the health technology assessment of complex interventions: A scoping review.PloS one · 2025Article
- A framework for improved collaboration on HTA in the Asia-Pacific region: a role for HTAsiaLink.International journal of technology assessment in health care · 2024Review
- Health technology assessment of medicinal products in Greece: a 5-year (2018-2023) review of timelines and productivity.International journal of technology assessment in health care · 2024Article
- How can health technology assessment be improved to optimise access to medicines? Results from a Delphi study in Europe : Better access to medicines through HTA.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study.BMJ (Clinical research ed.) · 2024Article
- Implicit factors influencing the HTA deliberative processes in 5 European countries: results from a mixed-methods research.Health policy OPEN · 2023Article
- Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement.International journal of technology assessment in health care · 2023Article
- Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile.Frontiers in pharmacology · 2022Article
- Article
- HTA Training for Healthcare Professionals: International Overview of Initiatives Provided by HTA Agencies and Organizations.Frontiers in public health · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.